Medicines Pipeline data

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) is requesting all current and potential Marketing Authorisation Holders (MAHs) to provide data regarding their planned medicine submissions over the next five years. This initiative is designed to improve the agency’s ability to forecast demand, allocate resources effectively, and ensure predictable assessment timelines, ultimately benefiting industry stakeholders and patient access. Under this regulatory framework, companies of all sizes are asked to share details such as product names, active ingredients, expected submission dates, and any additional services required, like Scientific Advice. For the off-patent and generic sectors, a simplified reporting requirement applies. To comply with this request, companies must download the provided MS Excel template from the MHRA website, populate it with the relevant pipeline information, and return it to the agency via email. The MHRA emphasizes that this data is non-binding and used solely for planning purposes; companies will not be held accountable if development timelines change. Data is stored securely in restricted folders, and the agency will reach out approximately every six months for updates. While this document does not list specific violations or inspection dates, it establishes a formal process for proactive communication between the regulator and the pharmaceutical industry to ensure the safety and efficacy of new treatments.